Journal of the National Comprehensive Cancer Network

Papers
(The median citation count of Journal of the National Comprehensive Cancer Network is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology704
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology578
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021568
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology513
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology513
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology502
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology472
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology433
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology431
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology362
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology329
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology324
NCCN Guidelines Insights: Rectal Cancer, Version 6.2020285
Role of Immunotherapy in Triple-Negative Breast Cancer277
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021277
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020276
Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal262
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020255
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology236
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology227
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology225
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020175
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology169
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021167
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021166
NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021160
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022156
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021146
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology141
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021140
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology127
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology126
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology115
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology114
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021104
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022100
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology89
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology86
NCCN Guidelines® Insights: Bladder Cancer, Version 2.202285
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.202185
NCCN Guidelines® Insights: Older Adult Oncology, Version 1.202176
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.202075
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology74
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology74
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.202273
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.202365
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.202062
Safety at the Time of the COVID-19 Pandemic: How to Keep Our Oncology Patients and Healthcare Workers Safe57
NCCN Guidelines Insights: Survivorship, Version 2.202057
NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.202251
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology51
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.202250
NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.202247
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology47
NCCN Guidelines® Insights: Breast Cancer, Version 4.202346
A Pilot Study of a Comprehensive Financial Navigation Program in Patients With Cancer and Caregivers43
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.202241
Functional Impairment, Symptom Burden, and Clinical Outcomes Among Hospitalized Patients With Advanced Cancer39
Impact of Telemedicine on Patient Satisfaction and Perceptions of Care Quality in Radiation Oncology39
Worry About Daily Financial Needs and Food Insecurity Among Cancer Survivors in the United States38
NCCN Guidelines® Insights: Palliative Care, Version 2.202136
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology36
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.202234
Survivorship, Version 1.202134
Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer32
Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology32
Neoadjuvant Immunotherapy–Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series32
Current Practices for Screening and Management of Financial Distress at NCCN Member Institutions31
Symptom Burden, Perceived Control, and Quality of Life Among Patients Living With Multiple Myeloma31
A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status31
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.202231
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience30
Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma30
Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review29
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.202128
Incident Cancer Detection During the COVID-19 Pandemic28
Conditional Survival and Cure of Patients With Colon or Rectal Cancer: A Population-Based Study27
Diagnostic and Therapeutic Delays in Patients With Hepatocellular Carcinoma26
Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab26
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology26
Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature25
Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma24
Adolescents and Young Adults Living With an Uncertain or Poor Cancer Prognosis: The “New” Lost Tribe24
Local Recurrence and Disease-Free Survival After Transanal Total Mesorectal Excision: Results From the International TaTME Registry24
Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer24
Impact of the First Generation of Children’s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor23
Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes23
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic23
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors22
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma21
NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.202321
Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer21
Role of Postoperative Radiotherapy in Nonmetastatic Head and Neck Adenoid Cystic Carcinoma20
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.202220
Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib20
NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.202320
Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology20
Pilot Randomized Trial of a Transdisciplinary Geriatric and Palliative Care Intervention for Older Adults With Cancer20
Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy20
Barriers to Optimal End-of-Life Care for Adolescents and Young Adults With Cancer: Bereaved Caregiver Perspectives20
Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer19
Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms19
Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma19
Effects of Postoperative Radiotherapy on Survival of Patients With Stage IIIA Resected Non–Small Cell Lung Cancer: Analysis of the SEER Database19
Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease19
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.202218
PTCH1-GLI1 Fusion–Positive Ovarian Tumor: Report of a Unique Case With Response to Tyrosine Kinase Inhibitor Pazopanib18
A Web-Based Tool to Automate Portions of Pretest Genetic Counseling for Inherited Cancer18
Defining and Managing High-Risk Multiple Myeloma: Current Concepts18
Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study18
Relationship Between Perceptions of Treatment Goals and Psychological Distress in Patients With Advanced Cancer18
The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer18
Outcomes and Predictors of 28-Day Mortality in Patients With Hematologic Malignancies and Septic Shock Defined by Sepsis-3 Criteria17
Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature17
Palliative Radiotherapy Versus Esophageal Stent Placement in the Management of Patients With Metastatic Esophageal Cancer17
Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts17
General and Health-Related Internet Use Among Cancer Survivors in the United States: A 2013–2018 Cross-Sectional Analysis16
Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response16
Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database16
Association Between Chronologic Age and Geriatric Assessment–Identified Impairments: Findings From the CARE Registry16
Cross-Sectional Analysis of the Associations Between Four Common Cancers and Disability16
Performance Status Restriction in Phase III Cancer Clinical Trials15
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study15
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy15
Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma15
Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair–Deficient Colorectal Cancer15
Cachexia and Dietetic Interventions in Patients With Esophagogastric Cancer: A Multicenter Cohort Study15
Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II–III Breast Cancer: A Multicenter Value Analysis15
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology15
Experience, Perceptions, and Recommendations Concerning COVID-19–Related Clinical Research Adjustments15
Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score–Matched Study15
Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer15
Non–Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment15
Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine14
Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer14
Outcomes of Patients With Cancer Discharged to a Skilled Nursing Facility After Acute Care Hospitalization14
Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma14
Patient Satisfaction and Quality of Life Before and After Treatment of Pancreatic and Periampullary Cancer: A Prospective Multicenter Study13
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.202313
Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy13
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology13
Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study13
Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 201913
Inherited Mutations in Chinese Men With Prostate Cancer13
Association of Polypharmacy and Potentially Inappropriate Medications With Physical Functional Impairments in Older Adults With Cancer13
Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor–Related Esophagitis13
Characteristics Associated With Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults13
Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance13
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial13
Re-Engage: A Novel Nurse-Led Program for Survivors of Childhood Cancer Who Are Disengaged From Cancer-Related Care12
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.202412
Impact of Axillary Dissection Among Patients With Sentinel Node–Positive Breast Cancer Undergoing Mastectomy12
Including DPYD on Cancer Genetic Panels to Prevent Fatal Fluoropyrimidine Toxicity12
Pediatric Hodgkin Lymphoma, Version 3.202112
NCCN Guidelines® Insights: Survivorship, Version 1.202212
Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease12
Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy12
Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond12
Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology11
Eligibility Criteria for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation11
Race- and Age-Related Disparities in Cervical Cancer Mortality11
Impact of Exercise on Chemotherapy Tolerance and Survival in Early-Stage Breast Cancer: A Nonrandomized Controlled Trial11
Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance11
Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer11
Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study10
Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant Chemotherapy10
Screening Tool Identifies Older Adults With Cancer at Risk for Poor Outcomes10
NCCN Guidelines® Insights: Distress Management, Version 2.202310
Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia10
Patterns and Trends of Cancer Screening in Canada: Results From a Contemporary National Survey10
The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?10
The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook10
Relationship Between Quality of Life and Survival in Patients With Pancreatic and Periampullary Cancer: A Multicenter Cohort Analysis10
Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time10
Risk of Cardiovascular Diseases Among Older Breast Cancer Survivors in the United States: A Matched Cohort Study10
Prevalence of Insomnia in an Oncology Patient Population: An Irish Tertiary Referral Center Experience10
Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC10
Immune-Related Adverse Events Among COVID-19–Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade10
Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer9
Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer9
Tumor Mutation Burden and Depression in Lung Cancer: Association With Inflammation9
Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials9
Diagnosis and Management of Rectal Cancer in Patients Younger Than 50 Years: Rising Global Incidence and Unique Challenges9
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology9
Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion9
Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer9
Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective9
Optimize Local Therapy for Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer to Enhance Survival9
Prevalence of Anemia and Compliance With NCCN Guidelines for Evaluation and Treatment of Anemia in Patients With Gynecologic Cancer9
Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis9
Current Surveillance After Treatment is Not Sufficient for Patients With Rectal Cancer With Negative Baseline CEA9
How Have Multigene Panels Changed the Clinical Practice of Genetic Counseling and Testing9
Challenges in the Histopathologic Diagnosis of Histiocytic Neoplasms9
Impact of Facility Surgical Volume on Survival in Patients With Cancer9
Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma8
What’s in a Number? Examining the Prognostic and Predictive Importance of Platelet Count in Patients With Essential Thrombocythemia8
Benefits of High-Volume Medical Oncology Care for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis8
Overuse of Diagnostic Brain Imaging Among Patients With Stage IA Non–Small Cell Lung Cancer8
Methylene Blue for the Treatment of Intractable Pain From Oral Mucositis Related to Cancer Treatment: An Uncontrolled Cohort8
Priority Rankings of Patient-Reported Outcomes for Pancreatic Ductal Adenocarcinoma: A Comparison of Patient and Physician Perspectives8
Guideline-Concordant Treatment Among Elderly Women With HER2-Positive Metastatic Breast Cancer in the United States8
Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes8
Improving Health Equity and Reducing Disparities in Pediatric and Adolescent/Young Adult Oncology: In Support of Clinical Practice Guidelines8
Underperformance of Contemporary Phase III Oncology Trials and Strategies for Improvement8
Serial Assessment of Urinary Incontinence in Breast Cancer Survivors Undergoing (Neo)Adjuvant Therapy8
Optimal Neoadjuvant Strategies for Locally Advanced Rectal Cancer by Risk Assessment and Tumor Location8
Blastic Plasmacytoid Dendritic Cell Neoplasm8
Validating a Patient-Reported Outcomes–Derived Algorithm for Classifying Symptom Complexity Levels Among Patients With Cancer8
Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative8
Depressive Symptoms in Danish Patients With Glioma and a Cancer-Free Comparison Group8
CLO20-054: A Phase 2 Trial of Nivolumab and Temozolomide in Advanced Neuroendocrine Tumors (NETs): Interim Efficacy Analysis8
Associations of Skeletal Muscle With Symptom Burden and Clinical Outcomes in Hospitalized Patients With Advanced Cancer8
Molecular Profiling of Endometrial Cancer From TCGA to Clinical Practice8
Paid Sick Leave Among Working Cancer Survivors and Its Associations With Use of Preventive Services in the United States7
Association of Social Support With Overall Survival and Healthcare Utilization in Patients With Aggressive Hematologic Malignancies7
Treatment of Stage IV Colon Cancer in the United States: A Patterns-of-Care Analysis7
Patient, Caregiver, and Oncologist Experiences With and Perceptions of Racial Bias and Discrimination in Cancer Care Delivery7
Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options7
Durable Response to PD-1 Blockade in a Patient With Metastatic Pancreatic Undifferentiated Carcinoma With Osteoclast-Like Giant Cells7
Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation7
Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study7
Impact of the Extent of Lymph Node Dissection on Precise Staging and Survival in Clinical I–II Pure-Solid Lung Cancer Undergoing Lobectomy7
Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival7
Outcomes of Patients With Advanced Gastrointestinal Cancer in Relationship to Opioid Use: Findings From Eight Clinical Trials7
Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma7
Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma7
Contemporary Population-Based Analysis of Bone Mineral Density Testing in Men Initiating Androgen Deprivation Therapy for Prostate Cancer7
Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report7
Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel7
Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients7
Update on Guidelines for the Prevention of Cancer-Associated Thrombosis6
Surgery After Response to Chemotherapy for Locally Advanced Pancreatic Ductal Adenocarcinoma: A Guide for Management6
NCCN Distress Thermometer Problem List Update6
SOURCE: Prediction Models for Overall Survival in Patients With Metastatic and Potentially Curable Esophageal and Gastric Cancer6
Navigating Nodal Metrics for Node-Positive Gastric Cancer in the United States: An NCDB-Based Study and Validation of AJCC Guidelines6
Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors6
Patients With cT1N0M0 Oral Squamous Cell Carcinoma Benefit From Elective Neck Dissection: A SEER-Based Study6
Sex- and Age-Related Differences in the Distribution of Metastases in Patients With Upper Urinary Tract Urothelial Carcinoma6
Benefit of Postoperative Radiotherapy for Patients With Nonmetastatic Adrenocortical Carcinoma: A Population-Based Analysis6
Expanding the Use of Nephron-Sparing Surgery for Wilms Tumor6
Mobile Technology-Based (mLearning) Intervention to Enhance Breast Cancer Clinicians' Communication About Sexual Health: A Pilot Trial6
Low Rates of Chemotherapy Use for Primary, High-Grade Soft Tissue Sarcoma: A National Cancer Database Analysis6
Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal6
Integration of Pediatric Hodgkin Lymphoma Treatment and Late Effects Guidelines: Seeing the Forest Beyond the Trees6
Evaluating if an Advance Care Planning Intervention Promotes Do-Not-Resuscitate Orders by Facilitating Accurate Prognostic Awareness6
Cancer Treatment During COVID-19: Resilience of Individuals With Advanced Non–Small Cell Lung Cancer Versus Community Controls6
Breast Cancer Diagnostics, Therapy, and Outcomes in Sub-Saharan Africa: A Population-Based Registry Study6
Quality of Life Is Associated With Survival in Patients With Gastric Cancer: Results From the Randomized CRITICS Trial6
Medicare/Medicaid Insurance, Rurality, and Black Race Associated With Provision of Hepatocellular Carcinoma Treatment and Survival5
Representation of Sexual and Gender Minority People in Patient Nondiscrimination Policies of Cancer Centers in the United States5
0.05374813079834